FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas
The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a trastuzumab-based regimen.